Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden hepatitis b may wake up during cancer treatment – study watches closely

NCT ID NCT06347588

Knowledge-focused Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 60 cancer patients who have a hidden form of hepatitis B (occult infection) and are receiving immunotherapy. The goal is to see how often the virus becomes active again, which could cause liver problems. Researchers will monitor blood tests and immune responses, but no new treatment is given. The findings may help doctors better manage these patients in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with solid tumors who have an occult hepatitis B infection and who need to start immunotherapy treatment.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Life-expectancy (as estimated by treating physician) ≥ 6 months; * Patients HBsAg negative * Patients HBcAb positive with or without HBV-DNA detectable * Patients with cancer undergoing immunotherapy with or without chemotherapy Exclusion Criteria: * Patients who did not give informed consent * Patients under prophylaxis for HBV * Patients vaccinated for hepatitis B * Patients with HBsAg positivity * Patients with HIV positivity * Patients with current history of alcohol (more than 5 alcohol unit daily) and drug use * Patients with other cause of liver disease with known etiology (autoimmune liver disorder and storage liver disease) * Patients with current active Hepatitis C virus (HCV-positive) * Patients with hepatocellular carcinoma (HCC)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Occult hepatitis B infection in cancer patients

Contacts and locations

Locations

  • Irccs San Matteo Pavia

    Pavia, PV, 27100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.